Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc. (MTNB)
Filing Type: Form 8-K (Current Report)
Report Date: November 8, 2021
Reporting Period: Quarter ended September 30, 2021
Context: This filing serves to announce the Company's financial results for the third quarter of 2021. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being located in the attached press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms that results for the quarter ended September 30, 2021, have been issued.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release containing the Company's commentary and results.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that Section, nor is it incorporated by reference in other filings unless expressly stated.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) to obtain specific revenue, net loss, and cash position figures for the quarter ended September 30, 2021.
- Verify year-over-year comparisons and specific operational milestones mentioned in the press release.
- Confirm the status of the Company's cash runway and any recent financing activities detailed in the full report.
- Note that the 8-K text itself does not constitute a "filed" document for liability purposes regarding the financial data contained in the press release.